
|Videos|January 23, 2017
Tarextumab in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Eileen M. O’Reilly, MD, discusses results of a randomized phase II trial of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5



















